Galectin Therapeutics Inc (PHPN)

Currency in EUR
3.100
+0.280(+9.93%)
Closed·
PHPN Scorecard
Full Analysis
RSI suggests the stock is in overbought territory
Trading near 52-week High
Fair Value
Day's Range
2.8203.100
52 wk Range
0.8153.100
Key Statistics
Bid/Ask
3.12 / 3.22
Prev. Close
2.82
Open
2.82
Day's Range
2.82-3.1
52 wk Range
0.815-3.1
Volume
-
Average Volume (3m)
868
1-Year Change
19.49%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PHPN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Galectin Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Galectin Therapeutics Inc Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Compare PHPN to Peers and Sector

Metrics to compare
PHPN
Peers
Sector
Relationship
P/E Ratio
−4.6x−4.5x−0.5x
PEG Ratio
−2.600.020.00
Price/Book
−1.8x3.1x2.6x
Price / LTM Sales
-192.4x3.2x
Upside (Analyst Target)
-168.8%42.0%
Fair Value Upside
Unlock8.9%6.6%Unlock

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.15 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PHPN Income Statement

People Also Watch

34.40
BMNR
+7.50%
7.880
HYPD
-10.05%
8.800
TRON
-5.27%
1.690
INVZ
+3.05%

FAQ

What Stock Exchange Does Galectin Therapeutics Inc Trade On?

Galectin Therapeutics Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Galectin Therapeutics Inc?

The stock symbol for Galectin Therapeutics Inc is "PHPN."

What Is the Galectin Therapeutics Inc Market Cap?

As of today, Galectin Therapeutics Inc market cap is 199.99M.

What Is Galectin Therapeutics Inc's Earnings Per Share (TTM)?

The Galectin Therapeutics Inc EPS (TTM) is -0.72.

From a Technical Analysis Perspective, Is PHPN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Galectin Therapeutics Inc Stock Split?

Galectin Therapeutics Inc has split 1 times.

How Many Employees Does Galectin Therapeutics Inc Have?

Galectin Therapeutics Inc has 15 employees.

What is the current trading status of Galectin Therapeutics Inc (PHPN)?

As of 30 Jul 2025, Galectin Therapeutics Inc (PHPN) is trading at a price of 3.10, with a previous close of 2.82. The stock has fluctuated within a day range of 2.82 to 3.10, while its 52-week range spans from 0.82 to 3.10.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.